Skip to main content

Table 2 Markers of bone turnover and bone regulators

From: Effect of cachexia on bone turnover in cancer patients: a case-control study

  All patients Patients without bone metastases
Cancer Cachexia (n = 31) Cancer
(n = 21)
p Cancer Cachexia (n = 28) Cancer
(n = 16)
p
CTX, ng/mL 0.38 (0.3–0.6) 0.31 (0.2–0.4) 0.08 0.38 (0.3–0.5) 0.27 (0.2–0.4) 0.03
Ocn ng/ml a 14.2 (± 5.5) 16.4 (± 5.3) 0.2 14.3 (± 5.6) 16.4 (± 4.4) 0.2
CTX/Ocn ratio > 0.022, n (%) 21 (67.7) 6 (28.6) 0.006 19 (67.9) 3 (18.8) 0.002
PINP, μg/L 32 (23–39) 27.5 (22–41) 0.6 31.9 (23–38) 26.1 (21–38) 0.5
CTX/PINP ratio > 0.011, n (%) 19 (61.3) 8 (38.1) 0,1 17 (60.7) 5 (31.3) 0.06
Corrected Ca, mmol/L 2.45 (2.4–2.6) 2.35 (2.3–2.4) 0.002 2.43 (2.4–2.5) 2.33 (2.3–2.4) 0.001
Phosphate, mg/dL 4.2 (4–4.4) 4.3 (4.2–4.6) 0.09 4.2 (4–4.4) 4.4 (4.2–4.6) 0.1
PTH, pg/mL 24.1 (18–34) 27 (23–32) 0.5 24.4 (19–34) 26.6 (23–32) 0.7
25(OH)D, ng/mL 14.4 (8–22) 13 (8–21) 0.7 15.1 (8–22) 13 (9–21) 0.8
TSH, μU/mL 1.7 (1.2–3.4) 1.3 (0.7–1.9) 0.03 1.7 (1–3.3) 1.2 (0.6–1.7) 0.02
  1. Abbreviations: CTX carboxy terminal telopeptide of collagen type I, Ocn osteocalcin, PINP procollagen type I N-terminal propeptides, 25(OH)D 25-hydroxy vitamin D
  2. - All variables are expressed as median and interquartile range (25-75th percentile), except for Ocn a(mean ± SD)